Sanofi will report its first-quarter 2026 results on April 23. The company showed strong revenue growth of 23.1% year-over-year in Q4 2025, reaching $13.53 billion. Its stock trades at a discount with a forward non-GAAP P/E ratio of 9.66x. Recently, Sanofi's blockbuster drug Dupixent received European Commission approval for treating certain children with chronic spontaneous urticaria, enhancing its growth prospects. These factors contribute to an attractive risk/reward profile as the stock enters an accumulation phase.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
